Life Extension Magazine®
The Hair RE-Growth Formulas Of |
Even for people who don't go completely bald, hair loss can be a problem. All people - both men and women - lose hair as they grow older. The hair they manage to hold onto becomes thinner and less pleasing to the eye and touch as it used to be. The Failure Of MinoxidilIn the 1980s, Americans were excited about Minoxidil. Minoxidil was developed as a blood pressure medication by The Upjohn Company. Researchers noticed that as a side effect, the drug grew hair. This "miraculous" abilty reached the public, who clamored for it. Finally Upjohn announced, with great fanfare, that it would seek FDA approval to market Minoxidil (now called " Rogaine") for baldness. As it turns out, however, Rogaine doesn't grow hair very well. Upjohn's latest version of the drug, which was recently approved by the FDA to be sold over-the-counter, is even less likely to work than the prescription version because it is half-strength. After eight years of clinical experience with Rogaine, the results have been mixed. Some people get benefit, others don't. It seems to work better in women than in men. However, it appears that Rogaine is much better at helping people keep and improve the hair they still have than in growing new hair. While some terminal hair does regrow in some people who use Rogaine, less than 10% show enough new growth in bald areas to cover them, especially in front. Those who grow a noticeable amount of hair tend to be people whose hair loss is at an early stage. In people with fine hair, the combination of regrowth plus "deminiaturization" of the existing hair can provide an acceptable cosmetic result about 40-50% of the time. As a bonus, most of these people stop getting balder. However, the expense, the side effects and the lack of efficacy of the drug prevent many people from using it. Although Minoxidil is the only FDA-approved treatment for baldness, people do not have to subject themselves to this drug to grow new hair. State-of-the art hair growth formulas have been developed by physician and scientist Peter Proctor, M.D., Ph.D. Androgenetic AlopeciaAlthough hair loss is part of aging, it occurs in young people who suffer from a condition called Androgenetic Alopecia (AGA), which leads to accelerated hair loss. AGA is commonly known as Male Pattern Baldness, but, in fact, occurs in both men and women. The pattern of hair loss varies by gender. With men it usually begins with a receding hair line. In women the pattern is more diffuse, typically sparing the anterior hairline and predominately affecting the crown. Pathogenesis Of Accelerated Hair LossThe current model of how accelerated hair loss (AGA) occurs involves a combination of genetic, hormonal and immunologic factors. Despite what some doctors (and TV infomercials) would have you believe, AGA has nothing to do with clogged hair follicles, which has been the basis for many "hair growth" products. Good scalp hygiene will improve the appearance of, and can add volume to, existing hair but will do nothing to prevent AGA or actually increase hair counts. There are at least 20 different products on the market today, which claim, either directly or indirectly, that they will grow hair or prevent baldness by "unclogging" hair follices. The effectiveness of virtually all of these products can be summed up in three simple words-they don't work! The only exception to this are the compounds Polysorbate 60 and Polysorbate 80-which are found in a few hair products, including LIFE EXTENSION SHAMPOO. Polysorbate 60 and 80 appear to be useful in slowing down hair loss when applied topically because of their ability to emulsify androgen-rich sebum deposits from the scalp. They are rarely able to generate any degree of hair regrowth, however, but may be useful in conjunction with other agents. Hormones, Immunity and HairThe latest scientific model to explain baldness involves the action of dihydrotestosterone (DHT)-the major metabolite of the male hormone testosterone. Scientists have found that excessive secretion of DHT stimulates a localized immune reaction, which, in turn, generates an inflammatory response that damages hair follicles, resulting in their miniaturization and eventual loss. What appears to happen is that DHT (and, perhaps, other androgenic hormones) causes the immune system to react to the hair follicles in the affected areas as foreign bodies. This is suggested by the presence of hair follicle antibodies as well as by the infiltration of immune system cells around the hair follicles of balding men and women. Blood vessel diseases such as atherosclerosis may also contribute to accelerated hair loss, as evidenced by the higher incidence of these diseases in balding persons. Successful prevention and treatment of accelerated hair loss necessitates dealing with some, if not all, of these factors involved in the process, except for the genetic component of baldness. Growing New Hair-Mechanism Of ActionIt is still unclear how Rogaine works. The active metabolite of the drug appears to be minoxidil sulfate. Speculation has centered around its ability to imitate hair growth factors produced by vessel linings such as nitric oxide and other endothelium-derived relaxing factors (EDRFs) If Rogaine is discontinued, the hair will go back to its former state. Rogaine In Combination With Similar AgentsWhen Rogaine is combined with tretinoin (Retin A), the results are significantly better than with Rogaine alone. Retin-A increases the percutaneous absorption of Rogaine and also appears to promote epithelial and vascular proliferation. Among the other hair-growth stimulators that appear to work in a manner similar to Rogaine are pyridine N-Oxides and their derivatives, Diazoxide, and Phenytoin (Dilantin), all of which probably also duplicate or enhance naturally occurring levels of endogenous hair growth stimulators such as EDRFs. In order to maintain a beneficial effect, Rogaine therapy must be continued forever. In many people, a tolerance effect develops after 2-3 years. As a result of this, the drug is often discontinued. Other Anti-Androgen Hair Growth AgentsSince the male hormone dihydrotestosterone is involved in premature hair loss, scientists have experimented with a wide variety of anti-androgens in an attempt to prevent or reverse the process. Among the anti-androgens that have been used to treat hair loss are: Progesterone, Spironolactone (Aldactone), Flutamide (Eulexin), Finasteride (Proscar), Cimetidine (Tagamet), Serenoa Repens (Permixon) and Cyproterone Acetate (Androcur/Diane). Of these anti-androgens the most effective have proved to be oral Finasteride (Proscar) and topical Spironolactone, both of which have been able to grow hair to some degree, with minimal side effects. ProscarProscar-which is already approved for the treatment of benign prostatic hypertrophy-is an inhibitor of 5-alpha reductase, the enzyme that converts testosterone into DHT. Proscar markedly reduces circulating levels of DHT, which inhibits the balding process. Preliminary data indicate that 58% of men on 5 mg. per day of Proscar will experience a 10% or greater increase in the total number of hairs on their heads. In virtually all the subjects receiving Proscar, there was a halt in the hair loss process. However, about 3-5% of them experienced a reversible decrease in libido and/or penile impotence. Proscar will probably be approved by the FDA for the treatment of hair loss, perhaps in 1 mg doses, within the next two years. PermixonPermixon, or saw palmetto extract, which also is used to treat benign prostatic hypertrophy, may also be of use in treating baldness. It is both a 5-alpha reductase inhibitor and blocks 50% of the uptake of DHT at its target tissue receptor sites. It has minimal side effects. To date, there have been no studies published in the medical literature evaluating the effects of Permixon on balding, though it is reasonable to assume that its benefits would be roughly equivalent to Proscar. SpironolactoneSpironolactone, a diuretic anti-hypertensive drug, is currently being prescribed as an anti-androgen therapy for the treatment of female hirsutism (excessive hair growth on the body) (Note: Androgens make body hair grow. They make scalp hair thin). It is also used to treat acne and AGA. Spironolactone blocks the formation and activity of testostosterone metabolites (such as DHT) entering hair follicles and oil glands by binding to the receptor protein. Spironolactone reduces scalp hair shedding and initiates scalp hair regrowth. Spironolactone is effective both topically and orally. Systemic use in men is precluded, however, because its anti-androgenic effect causes loss of libido and gynecomastia (larger-than-normal breasts). There are no side effects associated with the topical use of spironolactone, other than occasional contact dermatitis. The use of anti-androgens by themselves generally produces a very limited degree of hair regrowth. However, they are necessary and useful as adjuvants to other therapies such as hair-growth stimulators and oxygen free radical scavengers. Immunosuppression And Free Radical ScavengersThe immune response provoked by male hormones such as DHT probably plays the most significant role in balding. Stimulated by androgens, the immune system targets hair follicles in genetically susceptible areas to cause the premature loss of hair characteristic of male pattern baldness and other forms of accelerated hair loss. Thus, a side effect of the immunosuppressive drug cyclosporine (which is used to prevent the rejection of transplanted organs) is scalp hair regrowth. It may be that cyclosporine is the most potent single hair regrowth agent known. But the drug causes potentially severe toxic side effects when used systemically, including kidney damage, hypertension (high blood pressure)-and even death-which precludes its use as a hair growth stimulant. However, other ways (with no potential for system toxicity) have been found to inhibit the localized immune response that leads to hair loss. Topical Oxygen Radical ScavengersAmong the most potent hair growth stimulators are topical oxygen radical scavengers such as the superoxide dismutases (SODases)- enzymes that play a critically important role in countering excessive free radical activity throughout the body. Among the SODases that have been shown to promote hair growth are Tricomin, a patented copper tripeptide from the Procyte Corporation, and "Copperbinding Peptides" from Proctor & Gamble. To give you some idea of how mature this technology is getting, Proctor & Gamble has even patented an SODase inhibitor (DDTC) to block hair growth. SODases not only inhibit oxygen radicals, they also may inhibit the localized immune response responsible for so much of hair loss, and may offset some of the damage and inflammation already incurred. Unless the immunologic factors involved in the hair loss process are dealt with effectively in treatment, the potential for significant regrowth may be very limited. A Multi-Modal Approach To Hair TreatmentThere are many pharmaceutical agents (such as Rogaine) which can stimulate a degree of hair regrowth in some people. However, none of them alone can produce the kind of cosmetic benefits that balding people desire. What's needed is a multi-modal approach to hair treatment that combines anti-androgens with autoimmune protective agents, oxygen free radical inhibitors, and other hair growth stimulators to halt hair loss and generate hair regrowth to a degree well beyond the abilities of single compounds. Dr. Peter Proctor, M.D., Ph.D. |
Dr. Proctor Has Achieved an Unprecedented 80% Success Rate in Balding Patients with this Unique, Patented Hair Growth Formula! |
Life Extension Magazine (LEM) recently asked Dr.Proctor to answer some frequently asked questions about hair loss, baldness and the treatment of these conditions. Here are his answers. LEM: Who should be concerned about hair loss and balding? Dr.P: Many people over the age of 40 has already suffered significant hair loss caused by aging or disease, even if they think they still have a full head of hair. Persons below 30 should be especially concerned with hair loss if baldness runs in their family, or if they begin to notice the signs of Male Pattern Baldness. LEM: What are the signs of Male Pattern Baldness? Dr.P: Hair loss in a "pattern" typically beginning with recession in front and a bald patch in the back. LEM: When is the best time to start treatment for hair loss or baldness? Dr. P: The best time is as soon as possible after you notice any of the signs of hair loss. Before you notice any signs of hair loss, you might want to use shampoo that contains Polysorbate 60 and Polysorbate 80. If you're really concerned about preventing hair loss, you should use our single-agent Hair Regrowth Formula. LEM: Have your formulas proved successful in totally bald persons? Dr. P: No. With the partial exception of Alopecia Areata, where we have sometimes gotten pretty substantial regrowth of hair. LEM: How important are anti-androgens in the treatment of the balding process? Dr. P: Anti-androgens prevent the action of the hormones which initiate the balding process. Apparently, we were the first to use antiandrogens with hair growth stimulators and so can speak with some authority. For example, the Upjohn Corporation had a European patent (WO 92/0959) turned down in this area because of our "prior art" (WO A8700427) patent. Every five years or so, some new anti-androgen will be touted as the "ultimate solution for balding". Unfortunateiy, these never seem to work out. Thus, clinical trials with Cyoctal, a potent topical anti-androgen, were were terminated because of poor effectiveness. Apparently, balding is only partly an androgen problem. In fact, the primary follicle damage may be immunologically-mediated. Thus, anti-androgens work very poorly alone. However, they do make hair- growth-stimulators work much better and may prevent tolerance. Researchers developed the most recent anti-androgen, Proscar, because more powerful agents such as spironolactone (the one we use) are too potent to use orally. The idea is that the most important androgen for balding and prostate enlargement is DHT, while such side effects as breast growth are due to blockage of other androgens. Block DHT production alone and you might minimize the side-effects. This does work some, but Proscar is not entirely free of side-effects, nor does it work very well. Also, it is not topically effective. Currently, I prefer to use topical spironolactone because of its minimal side-effects and better effectiveness. LEM: What evidence is there that balding is immunologically-mediated? Dr. P: First, organ transplant drugs like cyclosporine reverse balding. They are too toxic for cosmetic purposes, but some new ones have just been patented listing hair loss as one application. Second, under the microscope the balding hair follicle looks like organ rejection. Finally, researchers have discovered antibodies to the hair follicle. LEM: How do you keep current in hair-loss treatment research? Dr. P: Because of the commercial applications, most new agents show up in the patent literature years before the medical literature. At last count, there were over forty U.S. patents and several hundred foreign patents covering hair-loss. Because of the expense and hassle of a patent, you can reasonably assume that it must work...at least in some young people. We're always being asked about this or that agent. If it is in the medical or patent literature, we probably know about it. We are always trying out new things. LEM: How does your research program compare to those of the major drug companies? Dr. P: Patent application dates, which have great legal importance, indicate we are several years ahead. Similarly, patents filed on our discoveries by later inventors have reaffirmed them. For example-to our dismay-the large Japanese drug company recently got a Japanese hair-growth patent using phenytoin, our invention. Likewise, the U.S. patent office just issued patents for hair growth using peptides with superoxide dismutase (SODase)/radical scavenging activity to the Procyte Corp. and to Proctor and Gamble. In the late 70s, we discovered this effect, using SODase to treat diabetic rats at Baylor College of Medicine. In fact, well before anyone else we applied for patents covering essentially all agents with this and related activity. European patents (e.g. EPO 89300785.6) have been granted allowing these broad claims. Conversely, the U.S. patent office originally thought our claims too broad for a single patent. But when we reapplied for patents on every compound, they were granted. |